Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Cervantes, Francisco; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Sirulnik, Andres; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S; Levy, Richard S; Passamonti, Francesco; Barbui, Tiziano; Barosi, Giovanni; Harrison, Claire N; Knoops, Laurent; Gisslinger, Heinz

Cervantes, Francisco; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Sirulnik, Andres; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S; Levy, Richard S; Passamonti, Francesco; Barbui, Tiziano; Barosi, Giovanni; Harrison, Claire N; Knoops, Laurent; Gisslinger, Heinz.

Affiliation

Cervantes F; Hospital Clínic, Hematology Department, Institut d'Investigació Biomédica August Pi i Sunyer, University of Barcelona, Barcelona, Spain;

Blood ; 122(25): 4047-53, 2013 Dec 12.

Article in En | MEDLINE | ID: mdl-24174625

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Protein Kinase Inhibitors / Primary Myelofibrosis Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Female / Humans / Male Language: En Journal: Blood Year: 2013 Document type: Article Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google